TrialThe British journal of dermatology2021

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.

R B Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.